1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Novo Nordisk A/S

Novo Nordisk A/S

NOVO.TO
Novo Nordisk A/SCA flagToronto Stock Exchange
16.12
CAD
-0.20
- -
53.94BMarket Cap
Novo Nordisk A/S
NOVO.TO
(Toronto Stock Exchange)

Recent

price

16.12

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
10.47
11.73
14.23
15.6
16.94
20.99
22.09
22.58
23.11
25.7
27.2
30.65
39.06
51.81
65.2
69.58
74.21
Revenue per Share
2.48
3.02
3.91
4.7
5.05
6.78
7.5
7.71
7.98
8.2
9.03
10.4
12.26
18.67
22.67
23.06
26.23
Basic EPS, GAAP
2.72
3.19
3.39
4.16
5.22
6.2
7.91
6.57
6.66
7.49
6.4
10.36
14.16
15.62
15.64
6.53
10.76
Free Cash Flow per Basic Share
0.76
1.01
1.41
1.81
2.26
2.51
4.71
3.81
3.94
4.09
4.31
4.68
5.58
7.09
9.91
11.65
11.71
Dividend per Share
6.16
6.46
7.26
7.74
7.6
9.03
8.88
9.96
10.58
12
13.47
15.31
18.55
23.9
32.31
43.67
50.01
Book Value per Share
5.92
6.2
6.99
7.45
7.34
8.62
8.34
9.3
9.53
10.78
9.08
5.97
7.23
10.35
7.35
14.4
22.42
Tangible Book Value per Share
5,805
5,654
5,483
5,359
5,244
5,142
5,060
4,946
4,839
4,749
4,668
4,594
4,531
4,483
4,454
4,442
4,439
Basic Weighted Avg Shares
60,776
66,346
78,026
83,572
88,806
107,927
111,780
111,696
111,831
122,021
126,946
140,800
176,954
232,261
290,403
309,064
329,431
Sales/Revenue/Turnover
31.08
33.72
37.77
37.68
38.84
45.81
43.33
43.84
42.25
43.01
42.64
41.65
42.28
44.16
44.19
41.3
43.13
Operating Margin (%)
2,467
2,737
2,693
2,799
3,435
2,959
3,193
3,182
3,925
5,661
5,753
6,025
7,362
9,413
8,545
14,666
19,843
Depreciation Expense
14,403
17,097
21,432
25,184
26,481
34,860
37,925
38,130
38,628
38,951
42,138
47,757
55,525
83,683
100,988
102,434
116,443
Net Income, GAAP
21.23
22.02
22.94
22.6
22.33
19.83
20.66
21.67
18.87
19.78
20.69
19.17
19.6
20.05
20.6
21.53
21.72
Effective Tax Rate (%)
23.7
25.77
27.47
30.13
29.82
32.3
33.93
34.14
34.54
31.92
33.19
33.92
31.38
36.03
34.78
33.14
35.35
Profit Margin (%)
18,817
18,812
18,525
17,833
12,604
14,267
12,330
13,024
4,903
3,473
-4,464
-13,921
-12,746
-30,009
-55,826
-43,208
-30,387
Working Capital
504
502
- -
- -
- -
- -
- -
- -
- -
3,009
2,897
12,961
24,318
20,528
89,674
118,941
121,794
LT Debt
36,965
37,448
40,632
42,569
40,294
46,969
45,269
49,815
51,839
57,593
63,325
70,746
83,486
106,561
143,486
194,047
221,277
Total Equity
38.02
43.86
56.42
56.57
60.67
83.38
76.18
73.07
68.92
69.94
60.88
53.92
56.09
64.64
51.89
34.23
33.4
Return on Invested Capital (%)
38.78
44.68
54.07
60.12
63.27
78.41
81.2
78.76
74.52
68.39
62.53
56.11
54.03
69.28
53.86
37.02
37.19
Return on Capital (%)
39.62
45.95
54.9
60.54
63.92
79.9
82.23
80.2
76
71.19
69.7
71.24
72
88.07
80.78
60.7
59.82
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
12,017
27,210
18,333
LT Borrowings
111,705
119,172
121,794
LT Finance Leases
7,236
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4,443
4,438
4,425
Market Capitalization
437,413
322,134
421,381

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
172,453
177,317
208,696
Cash, Cash Equivalents & STI
26,962
21,626
44,982
Accounts Receivable, Net
70,856
82,565
88,949
Inventories
49,623
51,352
51,352
Total Current Liabilities
215,661
225,158
239,083
Payables & Accruals
161,523
150,202
175,252
ST Debt
12,017
27,210
18,333
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.88%
25.45%
35.24%
Free Cash Flow
4.46%
8.88%
-58.38%
Net Income, GAAP
12.21%
20.48%
1.43%
Sales/Revenue/Turnover
11.61%
19.86%
6.43%
Total Cash Common Dividend
17.67%
21.26%
17.27%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
65,349
68,060
71,311
85,683
290,403
2025
78,087
76,857
74,976
79,144
309,064
2026
96,823
78,488
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5.7
4.5
6.13
6.35
22.67
2025
6.54
5.96
4.5
6.05
23.06
2026
10.93
4.74
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6.4
- -
3.5
- -
9.91
2025
7.95
-0.04
3.75
- -
11.65
2026
7.95
- -
- -
- -
- -
Similar Companies
Haw Par Corporation Limited (HAWPF)
JCR Pharmaceuticals Co., Ltd. (4552.T)
Gilead Sciences, Inc. (GILD)
Zhejiang Int'l Group Co.,Ltd. (000411.SZ)
Kopran Limited (KOPRAN.BO)
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (600613.SS)
Business
Novo Nordisk A/S is a global healthcare company that discovers, develops, manufactures and markets pharmaceutical products for diabetes, obesity care, rare diseases and related cardiometabolic conditions. Founded in 1923 and headquartered in Bagsværd, Denmark, the company operates worldwide and serves patients, healthcare providers and health systems through its Diabetes and Obesity Care and Rare Disease businesses. Its core portfolio includes insulin products; GLP-1-based therapies; oral antidiabetic medicines; obesity treatments; growth hormone and hormone replacement therapies; hemophilia and other rare blood disorder therapies; and related drug-delivery systems and services. Key brands and products include Ozempic®, Wegovy®, Rybelsus®, Saxenda®, Levemir®, NovoRapid®, Tresiba®, Norditropin®, and NovoSeven®, alongside pipeline and development assets targeting obesity, type 2 diabetes, MASH and rare diseases. Recent strategic changes center on portfolio expansion and manufacturing capacity. In 2025, Novo Nordisk entered multiple collaborations for oral obesity and cardiometabolic therapies, including an exclusive Septerna partnership and other licensing agreements to broaden its obesity modality toolkit. The company also completed the acquisition of Akero Therapeutics to add efruxifermin, a phase 3 FGF21 analogue for MASH, and secured an asset purchase and global license agreement for Omeros’ zaltenibart in rare blood and kidney disorders. It also said Catalent fill-finish sites are expected to add capacity from 2026, supporting future supply growth.